A medical device manufacturer spends 14 months preparing a 510(k) submission for the US market. The clearance arrives. The team celebrates.
Then someone asks about Europe.
The EU MDR requires a different clinical evidence package, a different quality management approach, a notified body assessment, and UDI compliance, none of which were planned in parallel. The European launch is delayed by two years. A competitor with a coordinated global strategy reaches both markets first.
This scenario is not hypothetical. It is the most common strategic failure in medical device commercialisation today.
Regulatory strategy has evolved from a final compliance hurdle into a foundational driver of commercial viability. Manufacturers who integrate regulatory planning from the earliest stages of product development reach patients faster, reduce redundant costs, and build defensible competitive positions across multiple markets simultaneously.
Insight Summary
✅ 89% of investors now consider regulatory intelligence a vital part of due diligence before funding a medical device company.
✅ Four once-in-a-decade transitions are converging in 2026: FDA QMSR, mandatory EUDAMED, UK reliance framework, and the EU AI Act.
✅ ISO 13485 harmonisation through QMSR means one quality system can now satisfy requirements across most major global markets.
✅ Go-to-market sequencing: sequential, parallel, or staggered, is now among the most consequential regulatory planning decisions.
✅ The regulatory affairs market is projected to reach USD 15.94 billion by 2035, compliance is a permanent, growing cost of doing business.
Why Regulatory Strategy Changed
Regulatory affairs was once positioned at the end of the product development cycle. Design the device. Build the device. Then figure out how to get it approved. That sequence no longer works.
The shift happened because regulatory complexity increased faster than most organisations adapted. The EU’s transition from the Medical Device Directive to the Medical Device Regulation raised clinical evidence requirements, expanded post-market surveillance obligations, and created a notified body capacity shortage that remains the single largest bottleneck in the European regulatory system. Meanwhile, the FDA modernised its quality system expectations, China’s NMPA tightened oversight, and emerging markets from Brazil to Oman introduced mandatory registration systems where none previously existed.
Manufacturers who treat each market as an isolated regulatory project duplicate effort, extend timelines, and burn capital. Those who architect a global-first strategy reduce redundant work, accelerate market access, and create defensible competitive positions.
Four Themes Defining 2026
The FDA’s adoption of ISO 13485 through QMSR is the most visible harmonisation milestone in a decade. Manufacturers with ISO 13485-aligned QMS now satisfy requirements across multiple jurisdictions simultaneously.
The EU AI Act now imposes direct obligations on medical device manufacturers. The FDA continues record-pace AI/ML device authorisations. Overlapping requirements demand coordinated compliance strategies.
Every major jurisdiction is strengthening post-market surveillance, clinical follow-up, and real-world evidence requirements. Lifecycle regulation has replaced point-of-clearance regulation.
From Botswana’s phased mandatory registration (April 2026) to Oman’s new high-risk device requirements, markets that previously operated informally now require structured regulatory submissions.
Key Regulatory Milestones in 2026
Several deadlines converging in 2026 make this year uniquely consequential for global regulatory planning.
FDA QMSR Enforcement Begins
The FDA replaced the legacy Quality System Regulation (21 CFR Part 820) with the Quality Management System Regulation, incorporating ISO 13485:2016 by reference. Inspections now evaluate compliance against this internationally harmonised standard.
EUDAMED Modules Become Mandatory
The European Commission confirmed that four key EUDAMED modules, actor registration, UDI device registration, certificates, and market surveillance, are now fully functional and mandatory.
UK International Reliance Framework
The UK proposed an international reliance framework recognising approvals from comparator regulators including Australia, Canada, the EU, and the United States. Operational details remain under development.
Health Canada Phase II Amendments
Health Canada’s Phase II amendments took effect, including adoption of the IMDRF table of contents for regulatory submissions, directly supporting harmonised global submission strategies.
Go-to-Market Sequencing: The Strategic Decision
Among the first and most consequential decisions in global regulatory planning is determining where to enter first and how to sequence subsequent submissions. Three models dominate.
The staggered approach has gained significant traction because it reduces redundant work through a unified technical dossier while managing risk through controlled sequencing. The IMDRF Table of Contents provides the structural foundation for building submission packages that serve FDA, EU, and other markets from a single core.
The Harmonisation Opportunity
The FDA’s QMSR transition represents a watershed moment for global regulatory alignment. By incorporating ISO 13485 by reference, the FDA effectively adopted the same quality management framework used by the EU, Canada, Japan, Australia, Brazil, and most MDSAP-participating countries.
For manufacturers, this creates a practical opportunity. A single ISO 13485-compliant quality management system can now satisfy requirements across multiple major markets simultaneously, reducing the need for parallel quality systems, duplicate documentation, and jurisdiction-specific procedures.
The opportunity extends beyond quality systems. Cybersecurity requirements are converging across jurisdictions. The FDA issued comprehensive cybersecurity guidance covering quality systems and premarket submissions. The UK published baseline security codes of practice for connected products. Manufacturers who develop harmonised cybersecurity approaches can satisfy multiple markets simultaneously rather than managing separate compliance programmes for each.
What Changes Next
Several developments will shape global regulatory strategy through 2027 and beyond.
The FDA is expected to release broader guidance on AI/ML-enabled software in late 2026, formalising requirements for managing algorithmic bias, ensuring diversity in training data, and implementing robust post-market monitoring. Manufacturers developing AI-enabled devices should prepare for overlapping obligations under both FDA guidance and the EU AI Act.
Notified body capacity in Europe remains constrained. New designations are expected throughout 2026 and 2027, but the gap between available capacity and industry demand continues to affect certification timelines. Some manufacturers are reconsidering EU market strategies entirely, shifting focus to markets with more predictable regulatory pathways.
Emerging markets continue formalising. Brazil’s ANVISA released its 2026-2027 regulatory agenda, including streamlined classification, public UDI databases, and mandatory MDSAP participation for international manufacturers. In the Middle East, Oman and Botswana are introducing phased mandatory registration systems. Asia Pacific remains one of the most dynamic regulatory regions, with Singapore, Japan, and South Korea all updating device frameworks.
Executive Takeaway
▶️ Audit your QMS against ISO 13485:2016 now: FDA QMSR inspections are already underway.
▶️ Prepare EUDAMED data: mandatory modules activate May 28, 2026.
▶️ Evaluate your go-to-market sequence: staggered strategies reduce redundant work while managing risk.
▶️ Build a harmonised core dossier using the IMDRF Table of Contents as your structural foundation.
▶️ Monitor AI/ML guidance: overlapping FDA and EU AI Act requirements will require coordinated compliance strategies.
The Strategic Imperative
The organisations that will lead the medical device industry over the next decade are not necessarily those with the most innovative technology. They are the ones that integrate regulatory planning into core business strategy from the earliest stages of product development.
Regulatory strategy is no longer about obtaining clearance. It is about architecting global market access, managing lifecycle obligations, protecting investment, and building the kind of regulatory intelligence that compounds over time.
The devices reaching patients fastest are not the ones designed first. They are the ones whose regulatory pathway was designed alongside the product itself.
Authoritative References
FDA (U.S. Food and Drug Administration)
- Quality Management System Regulation (QMSR), replaces 21 CFR Part 820 with ISO 13485:2016 alignment, effective February 2, 2026
- AI/ML-Based Software as a Medical Device Action Plan
- Cybersecurity Guidance for Quality Systems and Premarket Submissions
European Commission
- EU Medical Device Regulation (MDR) 2017/745
- EUDAMED, four mandatory modules activating May 28, 2026
- EU AI Act, obligations on AI-enabled medical device manufacturers from 2026
IMDRF & ISO
- IMDRF Table of Contents, structural foundation for harmonised global submissions
- ISO 13485:2016: Medical Devices Quality Management Systems
Industry Analysis
- MedEnvoy: 2025 Insights & 2026 Priorities
- MedTech Intelligence: Global Regulatory Landscape (Feb 2026)
- MedDeviceGuide: Regulatory Updates 2026
- Morgan Lewis: What Medtech Can Expect in 2026
- Compliance & Risks: Strategic Playbook (Apr 2026)
- SNS Insider: Regulatory Affairs Market Report (Jun 2026): USD 15.94B by 2035